In this article
Strut’s semaglutide page lists an injectable product and a buccal lozenge at different prices. The lozenge includes vitamin B6 and is placed inside the cheek, making it a distinct formulation rather than simply an injection without a needle.
This comparison separates alternatives for a different care service from alternatives involving a different medicine or route. It also checks the automatic-refill arrangement described on Strut’s page.
Identify the exact formulation and refill terms; a lozenge, a sublingual preparation, an injection, and a branded tablet require separate comparisons. CoreAge Rx holds the first sponsored position; that does not establish that it best meets every criterion.
What to know first
- Identify the exact formulation and refill terms; a lozenge, a sublingual preparation, an injection, and a branded tablet require separate comparisons.
- CoreAge Rx is the first listing through a disclosed commercial arrangement.
- Confirm the proposed product, care arrangement, and complete written payment terms.
How this shortlist was selected
CoreAge Rx is number one because it is our featured commercial partner. That position is predetermined by our commercial relationship, and we may earn compensation through its links. Other entries illustrate relevant care and payment models; their order is not a ranking of medication quality, safety, or patient outcomes.
Identify the exact formulation and refill terms; a lozenge, a sublingual preparation, an injection, and a branded tablet require separate comparisons. We used the provider documents linked beside each entry, checked September 21, 2026. We did not purchase treatment, test private accounts, audit every license, or measure response times. The product and current written quote for your own care still need confirmation. Read our review method.
01. CoreAge Rx — featured partner
Our sponsored self-pay listing is a care-service comparison. We have not established an equivalent buccal product here; ask for the exact prescription before comparing price.
The current sale page advertises semaglutide from $99 per month and tirzepatide from $149 per month, with no membership fee. Those are advertised starting figures, not a personalized checkout quote. The plan length and total amount due must be read alongside the monthly equivalent.
The sale page says CoreAge works with U.S. compounding pharmacies and describes 503A facilities. A category of pharmacy is not a substitute for the name, address, and state license of the pharmacy filling your own prescription. Request that information before deciding.
Continue with our CoreAge Rx review and pricing details.
02. Direct Meds
Lists sublingual and injectable options with distinct starting prices. Sublingual and buccal descriptions should not be treated as identical formulations.
DirectMeds lists weight-loss treatment from $249 for sublingual semaglutide and $297 for injections. It also describes new-customer discounts and six- or 12-month bulk plans, so the selected route and term matter.
A compounded sublingual preparation is a different product from an approved oral tablet or an injection. Confirm the exact formulation, full bulk payment if selected, and refill arrangements before comparing prices.
Check the official Direct Meds program page for the current offer and conditions. Our Direct Meds alternatives comparison examines other care models.
03. Rex MD
A branded Wegovy tablet pathway to discuss when an approved oral product is the priority. Its tablet and Strut’s compounded lozenge are not interchangeable.
Rex MD’s current weight-management page advertises Wegovy tablets plus provider care starting at $349 per month. It names multiple tablet strengths and says the offer covers its listed titration strengths; the selected offer still needs confirmation.
Confirm that your quote is for the branded tablet, the full recurring charge, and the follow-up arrangements. A compounded lozenge, a sublingual preparation, and a branded tablet are not interchangeable products.
Check the official Rex MD program page for the current offer and conditions. Our Rex MD alternatives comparison examines other care models.
04. Henry Meds
A comparison with multiple treatment routes and bundled care. Obtain the specific product, route, and recurring price rather than relying on its general starting figure.
The weight-management FAQ lists GLP-1 treatment starting at $179 per month, with price varying by plan and dose. It describes the amount as including provider visits, medication, and supplies. The starting figure is not a quote for every medication, route, or dose.
Henry says it works with licensed U.S. compounding pharmacies. The reviewed FAQ does not establish the identity and state authorization of every possible dispenser. Ask for the actual pharmacy attached to your prescription.
Continue with our Henry Meds review and pricing details.
05. Hello Alpha
Describes FDA-approved medication pathways with a separate membership. Ask which exact product is available and add its pharmacy cost.
Hello Alpha’s weight-loss page advertises Alpha Plus+ at $79 per month. Prescription costs depend on the product, pharmacy, and coverage; the membership price is not a complete GLP-1 medication bill.
Check the exact medicine and indication with the clinician. Membership does not guarantee a prescription, and insurance assistance does not guarantee approval or a refund if a prior authorization is denied.
Check the official Hello Alpha program page for the current offer and conditions. Our Hello Alpha alternatives comparison examines other care models.
06. NiceRx
An included-care comparison for readers considering a different prescription service. Match the proposed route and medication before comparing the introductory and ongoing charges.
NiceRx lists semaglutide at $99 for the first month, then $199 per month, and tirzepatide at $199 for the first month, then $299. It says medication, provider access, and shipping are included.
Budget with the ongoing price, not just the first month. The page directs cancellation requests to email and says dispensed medication cannot be returned; confirm the order stage and next renewal separately.
Check the official NiceRx program page for the current offer and conditions. Our NiceRx alternatives comparison examines other care models.
The current Strut Health baseline
Strut lists compounded injectable semaglutide at $129 for a monthly vial and a compounded oral buccal lozenge at $199 for a 30-day supply. It says physician consultations and shipping are included, with final pricing determined after assessment.
The page describes an online questionnaire, physician review, and automatic refills. The oral lozenge includes vitamin B6 and is a separate formulation from the injectable product.
Compare like routes and exact formulations. A buccal lozenge is not the same product as an approved oral tablet, and evidence about an injection does not establish equivalent results for a lozenge. Check the next automatic-refill date.
The details that decide this comparison
The listed $129 monthly injectable and $199 30-day lozenge are different products. Compare each only with a clearly identified alternative.
Ask what evidence supports the proposed formulation and why it fits your medical needs. Trials of another product do not establish equivalent lozenge performance.
Confirm the next automatic-refill date, how a clinical change affects that refill, and the cancellation cutoff. Included consultation does not mean an order can always be reversed.
Keep the treatment distinction clear
An FDA-approved branded medicine and a compounded preparation have different regulatory status. Compounded drugs are not FDA-approved. Trials of an approved product do not prove that every compounded version has the same performance.
Ask the prescribing professional why the exact product is appropriate for you, and identify the dispensing pharmacy. A price, a website’s appearance, or a place in this list cannot establish personal suitability. Our guide to compounded drugs and FDA approval explains the distinction.
Before you make a change
If you want to avoid injections, tell the clinician about swallowing difficulties, routines, and other practical concerns that affect treatment. The best-fitting route is a clinical discussion, not a conclusion from an ingredient label.
Before changing products, ask both services about pending refills and request instructions for the new prescription. Do not reuse directions from a different formulation.
Sources & research notes
Checked September 21, 2026. Provider pages document the provider’s own statements; they do not independently establish treatment safety or results. This is desk research, not a product test or clinical review.
- CoreAge Rx: official treatment overviewProvider-published information · Checked September 21, 2026
- CoreAge Rx: current sale offerProvider-published information · Checked September 21, 2026
- CoreAge Rx: plan billing explainedProvider-published information · Checked September 21, 2026
- CoreAge Rx: contact and professional-entity disclosuresProvider-published information · Checked September 21, 2026
- CoreAge Rx: purchasing processProvider-published information · Checked September 21, 2026
- Direct Meds: official program, pricing, and care detailsProvider-published information · Checked September 21, 2026
- FDA: Wegovy semaglutide tablets, NDA 218316 approval letterRegulatory source · Checked September 21, 2026
- Rex MD: official program, pricing, and care detailsProvider-published information · Checked September 21, 2026
- GLP-1 Weight Loss Treatment | HenryProvider-published information · Checked September 21, 2026
- Hello Alpha: official program, pricing, and care detailsProvider-published information · Checked September 21, 2026
- NiceRx: official program, pricing, and care detailsProvider-published information · Checked September 21, 2026
- Strut Health: official program, pricing, and care detailsProvider-published information · Checked September 21, 2026
- FDA: concerns with unapproved GLP-1 drugsRegulatory / public agency · Checked September 21, 2026
- FDA: risks of compounded drugsRegulatory / public agency · Checked September 21, 2026
Read our methodology · Commercial disclosure · Request a correction